Key result
AT2R agonist β-Pro7-AngIII inhibits salt-induced cardiac and renal fibrosis and inflammation in mice.
Why the study?
Activation of the AT2R is considered organ protective in cardiovascular diseases, but there are limited AT2R-selective agonists available.
Does β-Pro7-AngIII reduce cardiac and renal fibrosis and inflammation in high salt-fed mice?
Does β-Pro7-AngIII reduce cardiac and renal fibrosis and inflammation in high salt-fed mice?
The novel AT2R-selective agonist β-Pro7-AngIII demonstrates cardio- and reno-protective anti-fibrotic and anti-inflammatory effects in a high salt-fed mouse model.
AT2R agonism may attenuate salt-induced fibrosis preclinically; leaves open translation to human cardio-renal disease.
A high salt (HS) diet is associated with an increased risk for cardiovascular diseases (CVDs) and fibrosis is a key contributor to the organ dysfunction involved in CVDs. The activation of the renin angiotensin type 2 receptor (AT2R) has been considered as organ protective in many CVDs. However, there are limited AT2R-selective agonists available. Our first reported β-substituted angiotensin III peptide, β-Pro7-AngIII, showed high selectivity for the AT2R. In the current study, we examine the potential anti-fibrotic and anti-inflammatory effects of this novel AT2R-selective peptide on HS-induced organ damage. FVB/N mice fed with a 5% HS diet for 8 weeks developed cardiac and renal fibrosis and inflammation, which were associated with increased TGF-β1 levels in heart, kidney and plasma. Four weeks’ treatment (from weeks 5–8) with β-Pro7-AngIII inhibited the HS-induced cardiac and renal fibrosis and inflammation. These protective effects were accompanied by reduced local and systemic TGF-β1 as well as reduced cardiac myofibroblast differentiation. Importantly, the anti-fibrotic and anti-inflammatory effects caused by β-Pro7-AngIII were attenuated by the AT2R antagonist PD123319. These results demonstrate, for the first time, the cardio- and reno-protective roles of the AT2R-selective β-Pro7-AngIII, highlighting it as an important therapeutic that can target the AT2R to treat end-organ damage.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) studied High salt-induced cardiac and renal fibrosis and inflammation. β-Pro7-AngIII vs. High salt diet alone / PD123319 was evaluated on Cardiac and renal fibrosis and inflammation. The AT2R-selective agonist β-Pro7-AngIII inhibited high salt-induced cardiac and renal fibrosis and inflammation in mice, effects that were attenuated by the AT2R antagonist PD123319.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: